Inovio 3Q25 Review: EPS Miss, $25M Offering, And INO-3107 Progress [Seeking Alpha]
Inovio Pharmaceuticals, Inc. (INO)
NASDAQ:AMEX Investor Relations:
ir.inovio.com/investors/default.aspx
Company Research
Source: Seeking Alpha
INO ended the quarter with $50.8 million in cash, expects a runway into 2Q26, and announced a $25 million public offering to support operations. Key pipeline progress includes completion of the BLA submission for INO-3107, with hopes for FDA priority review and potential U.S. launch by mid-2026. INO trades at sector-comparable valuations but remains a high-risk, event-driven biotech; future gains hinge on INO-3107 approval and successful commercialization. STAP/E+ via Getty Images Thesis Inovio Pharmaceuticals ( INO ) earnings yesterday didn't impress many, with the stock initially sliding 12%. 3Q25 saw a GAAP EPS loss of -$0.87, missing consensus estimates by $0.45. The company managed to end the quarter with $50.8 million in cash, cash equivalents, and This article was written by Analyst's Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrot
Show less
Read more
Impact Snapshot
Event Time:
INO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
INO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
INO alerts
High impacting Inovio Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
INO
News
- Inovio Pharmaceuticals (NASDAQ:INO) had its "sell (d-)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- INOVIO to Participate in December Investor ConferencesPR Newswire
- Individual investors invested in Inovio Pharmaceuticals, Inc. (NASDAQ:INO) lost 13% last week, institutions remained on the sidelines [Yahoo! Finance]Yahoo! Finance
- Inovio Pharmaceuticals (NASDAQ:INO) had its "overweight" rating reaffirmed by analysts at UBS Group AG.MarketBeat
- Inovio Pharmaceuticals (NASDAQ:INO) had its "overweight" rating reaffirmed by analysts at Piper Sandler.MarketBeat
INO
Earnings
- 11/10/25 - Miss
INO
Sec Filings
- 12/5/25 - Form SCHEDULE
- 11/14/25 - Form SCHEDULE
- 11/14/25 - Form SCHEDULE
- INO's page on the SEC website